Opinion
50mOpinion
FDA’s abrupt flip-flop on Moderna’s mRNA flu shot highlights growing risks to drug-makers of investing in vaccines
Moderna’s proposed mRNA-based flu vaccine set off a firestorm of criticism from public health experts. But just a week later, on Feb. 18, the FDA backtracked on its decision, saying that it will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results